A new report by stakeholder intelligence firm alva has revealed the leaders in the pharma industry when it comes to equality, diversity and inclusion (EDI) - and Bayer (BAYN: DE) tops the list.
Post-pandemic, EDI is becoming a strategic imperative for pharma organisations as firms compete to recruit top talent.
"More diverse companies are better able to win top talent and improve their customer orientation, employee satisfaction and decision making"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze